Person:
GEPDİREMEN, ALİ AKÇAHAN

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
ALİ AKÇAHAN
Last Name
GEPDİREMEN
Name
Email Address
Birth Date

Filters

20201
Reset filters

Settings

Subject: RAAS ×

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    PublicationOpen Access
    ACE-2, TMPRSS2 and Beyond; Promising Targets and Tools for COVID-19 Prophylaxis and Treatment
    (2020-12-01T00:00:00Z) Gepdiremen, Ali Akçahan; Kumaş, Meltem; GEPDİREMEN, ALİ AKÇAHAN
    Several repurposing drugs and ongoing vaccine researches tocombat Coronavirus Disease-19 (COVID-19) are testing clinically,worldwide. COVID-19 caused by severe acute respiratory failuresyndrome-CoV-2, uses angiotensin-converting enzyme 2 (ACE-2) as a functional receptor for entry into the cells, followed by itspriming by transmembrane protease serine 2 (TMPRSS2). Most ofthe ACE-2 expressing cells are alveolar type II pneumocytes. ViralS-glycoprotein, TMPRSS2 and ACE-2 inhibition, as extracellularmedia components, are potential targets of future therapy. ACE-2 and/or TMPRSS2 blockade is thought to be beneficial in theprevention or treating of this infection which will be the mostconvenient for pharmacoeconomics and effectiveness, regardingsimilar future pandemics. Despite substrate-based design andsynthesis of ACE-2 inhibitor compounds were presented almosttwo decades ago, data on renin angiotensin system activation orits blockers, especially ACE-2, are limited by now. Priority mustbe given to design a convenient vaccine soon, but due to the highmutation ability of such viruses mean that new vaccines may needto be developed for each outbreak. So, de novo drugs such as ACE-2or TMPRSS2 blockers need to be developed which can specificallyblock spike binding sites of the target cells and prevent virusintrusion, especially at the extracellular media, for future pandemics.